ATE246515T1 - Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac - Google Patents

Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac

Info

Publication number
ATE246515T1
ATE246515T1 AT94918361T AT94918361T ATE246515T1 AT E246515 T1 ATE246515 T1 AT E246515T1 AT 94918361 T AT94918361 T AT 94918361T AT 94918361 T AT94918361 T AT 94918361T AT E246515 T1 ATE246515 T1 AT E246515T1
Authority
AT
Austria
Prior art keywords
pct
oral dosage
formulations containing
dosage formulations
containing diclofenac
Prior art date
Application number
AT94918361T
Other languages
English (en)
Inventor
Peter Heinrich Stahl
Claudio Gamboni
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE246515T1 publication Critical patent/ATE246515T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT94918361T 1993-06-08 1994-05-24 Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac ATE246515T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH171193 1993-06-08
PCT/EP1994/001662 WO1994028936A1 (en) 1993-06-08 1994-05-24 Process for the preparation of an oral solid dosage form containing diclofenac

Publications (1)

Publication Number Publication Date
ATE246515T1 true ATE246515T1 (de) 2003-08-15

Family

ID=4216820

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94918361T ATE246515T1 (de) 1993-06-08 1994-05-24 Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac

Country Status (14)

Country Link
US (1) US5702724A (de)
EP (1) EP0701449B1 (de)
JP (2) JPH08511009A (de)
AT (1) ATE246515T1 (de)
AU (1) AU6971294A (de)
CA (1) CA2163111C (de)
DE (1) DE69433012T2 (de)
DK (1) DK0701449T3 (de)
ES (1) ES2204918T3 (de)
FI (1) FI116039B (de)
NO (1) NO315844B1 (de)
NZ (1) NZ267417A (de)
PT (1) PT701449E (de)
WO (1) WO1994028936A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT800384E (pt) * 1994-12-14 2001-06-29 Enbalt Trading Ltd Metodo para a preparacao de um comprimido farmaceutico
HUP9600758A2 (en) * 1996-03-27 1998-03-02 Cyclolab Ciklodextrin Kutato F Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
US6720005B1 (en) * 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
JP2005298338A (ja) * 2002-02-27 2005-10-27 Eisai Co Ltd 速崩壊性圧縮成形製剤
RU2318497C2 (ru) * 2002-03-07 2008-03-10 Новартис Аг Фармацевтические композиции
US20040241234A1 (en) * 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
EP1707217A1 (de) * 2004-12-17 2006-10-04 Wacker Chemie AG Methode zur Herstellung eines Alpha-Liponsaure/cyclodextrin Komplexes sowie das hersgestellte Produkt
DE102004060914A1 (de) * 2004-12-17 2006-07-06 Bioghurt Biogarde Gmbh & Co. Kg Verwendung von Liponsäure-haltigen Cyclodextrin-Komplexen
MX2008012496A (es) * 2006-03-28 2009-01-07 Javelin Pharmaceuticals Inc Formulaciones de farmacos anti-inflamatorios no esteroidales de baja dosis y beta-ciclodextrina.
EP2522343A1 (de) * 2006-03-28 2012-11-14 Javelin Pharmaceuticals, Inc. Formulierungen aus niedrigdosiertem Diclofenac und Beta-Cyclodextrin
US20110144207A1 (en) * 2008-08-14 2011-06-16 Shasun Chemicals And Drugs Limited Aryl alkyl carboxylic acid salts, process for preparation and dosage forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5959632A (ja) * 1982-09-28 1984-04-05 Teikoku Chem Ind Corp Ltd 徐放性組成物
JPS5984821A (ja) * 1982-11-04 1984-05-16 Teikoku Chem Ind Corp Ltd 徐溶化組成物
FR2660195B1 (fr) * 1990-03-28 1994-10-07 Crinex Sa Laboratoires Composition pharmaceutique a macher, antiinflammatoire et/ou analgesique.
IT1243342B (it) * 1990-07-13 1994-06-10 Farcon Ag Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria
DE69013689T2 (de) * 1990-11-29 1995-03-02 Wei Ming Pharmaceutical Mfg Co Hilfsträger für direkte Verpressung.
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine

Also Published As

Publication number Publication date
US5702724A (en) 1997-12-30
JPH08511009A (ja) 1996-11-19
ES2204918T3 (es) 2004-05-01
EP0701449B1 (de) 2003-08-06
EP0701449A1 (de) 1996-03-20
FI955837A0 (fi) 1995-12-04
NZ267417A (en) 1997-02-24
WO1994028936A1 (en) 1994-12-22
NO954952D0 (no) 1995-12-06
NO315844B1 (no) 2003-11-03
DK0701449T3 (da) 2003-11-10
FI116039B (fi) 2005-09-15
DE69433012T2 (de) 2004-06-09
AU6971294A (en) 1995-01-03
DE69433012D1 (de) 2003-09-11
PT701449E (pt) 2003-12-31
CA2163111A1 (en) 1994-12-22
CA2163111C (en) 2010-10-26
NO954952L (no) 1995-12-06
FI955837L (fi) 1995-12-04
JP2005247874A (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
BR9407239A (pt) Azadioxacicloalquenos substituídos
PL314188A1 (en) Novel derivatives of benzoguanidine, method of obtaining them and their application in pharmaceutical compositions
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
HUT72970A (en) Risperidone pamoate, pharmaceutical composition containing it and process for their production
PT99513A (pt) Processo para a preparacao de composicoes farmaceuticas contendo profarmacos de morfina para administracao topica por via transdermica
DE69433012D1 (de) Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac
WO1990009993A3 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
HUT77627A (hu) 2,2-Diklór-alkánkarbonsavak, eljárás előállításukra és ezeket tartalmazó, inzulinrezisztencia kezelésére alkalmazható gyógyszerkészítmények
ATE112239T1 (de) Vaterit und verfahren zu dessen herstellung.
GB9424766D0 (en) Pharmaceutical composition
ES2131528T3 (es) Nuevos polipeptidos y su uso.
ATE236139T1 (de) Verfahren zur herstellung von 2-chlor-5- chlomethyl-thiazol-derivaten
DE69314779D1 (de) Prozess zur herstellung von beta-phenylisoserin und analogen verbindungen
ATE110723T1 (de) Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung.
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
DE69104220D1 (de) Verfahren zur Herstellung von direktkomprimierten, Cephalosporansäure Derivate enthaltendenTabletten.
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
TW252979B (de)
ATE135681T1 (de) Diclofenac-cholinsalz, verfahren zur herstellung und pharmazeutische zusammensetzungen, die es enthalten
ATE216237T1 (de) Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade
ATE173922T1 (de) 2-arylpropionsäure-zubereitungen und verfahren zu ihrer herstellung
DE69210069D1 (de) Verfahren zur Herstellung von 1,3-Dioxolen
TW261605B (de)
ATE160938T1 (de) Feste orale pharmazeutische zubereitung mit gemfibrozil als aktiver inhaltsstoff und verfahren zur herstellung
DE59409413D1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0701449

Country of ref document: EP